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Background: Sirtuin 3 (Sirt3), one of the seven Sirtuins family members, plays critical roles in the progression of
multiple cancer types. However, its role in the prognosis of hepatocellular carcinoma (HCC) has not yet been
investigated systematically.
Methods: The correlation of Sirtuins expression with prognosis of HCC was determined by immunohistochemistry
(IHC) in a large HCC patient cohort (n = 342). Expression of Sirt3 in tumoral and peritumoral tissues of HCC patients
were further determined by western blotting (WB).
Results: IHC and WB studies both showed a decreased expression of Sirt3 in tumoral tissues compared with
peritumoral tissues (P = 0.003 for IHC, P = 0.0042 for WB). Decreased expression of Sirt3 in both tumoral and
peritumoral tissues was associated with increased recurrence probability and decreased overall survival rate by
univariate analyses (intratumoral Sirt3: P = 0.011 for TTR, P = 0.001 for OS; peritumoral Sirt3: P = 0.017 for TTR,
P = 0.023 for OS), the prognostic value was strengthened by multivariate analyses (intratumoral Sirt3: P = 0.031
for TTR, P = 0.001 for OS; peritumoral Sirt3: P = 0.047 for TTR, P = 0.031 for OS). Intratumoral Sirt3 also showed a
favorable prognostic value in patients with BCLC stage A (TTR, P = 0.011; OS, P < 0.001). In addition, we found
that IHC studies of other sirtuin members showed a decreased expression of Sirt2, Sirt4 and Sirt5 and an
increased expression of Sirt1, Sirt6 and Sirt7 in intratumoral tissues compared with peritumoral tissues. In
contrast to Sirt3, other members did not showed a remarkable correlation with HCC prognosis.
Conclusions: Down-regulation of intratumoral and peritumoral Sirt3 were both associated with poor outcome in
HCC, moreover, intratumoral Sirt3 was a favorable prognostic predictor in early stage patients.
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Hepatocellular carcinoma (HCC), with rising incidence
in the west, is the third leading cause of cancer-related
death worldwide [1]. Although many advances in HCC
therapy had been reached, surgical resection and liver
transplantation remain the most reliable curative treat-
ment modalities for selected patients. One of the major* Correspondence: qiu.shuangjian@zs-hospital.sh.cn
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reproduction in any medium, provided the orobstacles for improved outcome after resection is the
high frequency of recurrence. It was proposed that react-
ive oxygen species (ROS) produced by mitochondria was
participated in HCC progression and metastasis, through
promoting DNA damage or altering cellular signaling
pathways [2-5]. Recently, Sirt3 has emerged as a critical
modulator of mitochondria function by reducing mito-
chondria membrane potential and ROS levels [6-9].
The Sirtuins, a family of orthologues of yeast silent in-
formation regulator 2 (Sir2) found in a wide range of or-
ganisms from bacteria to human, regulate metabolism;
cellular proliferation and survival; stress resistance and
apoptosis, and participate in metabolic; cardiovasculartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Clinicopathologic features of the patients
Age, y, median (range) 53 (10 ~ 70)
Gender (male/female) 290/52
Hepatitis infection (no/yes) 94/248
Liver cirrhosis (no/yes) 38/304
AFP, ng/ml, median (range) 98.5 (0 ~ 60500)
γ-GT, U/L, median (range) 57 (7 ~ 693)
ALT, U/L, median (range) 39 (8 ~ 949)
Child-Pugh score (A/B) 342/0
Tumor size, cm, median (range) 4 (1.0 ~ 21.0)
Tumor number (single/multiple) 298/44
Tumor capsule (yes/no) 183/159
Tumor differentiation (I/II/III/IV) 7/248/85/2
Tumor thrombi (no/yes) 249/93
TNM stage (I/II&III) 154/188
BCLC stage (A/B&C) 233/109




Abbreviations: AFP, alpha-fetoprotein; γ-GT, gamma-glutamyl transpeptidase;
ALT, alanine transaminase; TNM, tumor-node-metastasis; BCLC, Barcelona Clinic
Liver Cancer; TACE, transcatheter arterial chemoembolization.
a. immunotherapy: interferon-α or thymosin therapy.
b. regional: radio frequency ablation (RFA), percutaneous ethanol injection
therapy (PEI) or microwave ablation (MA); others: traditional Chinese
medicine etc.
c. others: thrombi from hepatic vein, inferior caval vein or intrahepatic ducts.
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cers [10-12]. Sirt3, a member of the family, functions
mainly as the primary mitochondrial deacetylase that
modulates mitochondrial metabolic and oxidative stress
regulatory pathways [9,13,14]. Published data revealed
that Sirt3 was implicated in tumor progress [15,16],
mainly through mediating the suppression of hypoxia in-
ducible factor 1α (HIF-1α) and inhibiting mitochondrial
ROS production [17,18]. The proliferation-suppressor
role of Sirt3 was confirmed in multiple cancer types, in-
cluding breast cancer and colon cancer, both in vitro
and in vivo [6,18]; it was also reported that Sirt3 could
inhibit HCC cell growth through reducing Mdm2-
mediated p53 degradation [19]. However, the expression
status of Sirt3 in human HCC specimens is still ambigu-
ous and the relationship between Sirt3 expression and
cancer prognosis is still unclear. Hence, further intensive
investigation is substantial.
In this study, we evaluated the expression status of the
Sirtuin family members (Sirt1-7), mainly focusing on
mitochondria member Sirt3, in a large HCC cohort by
IHC staining. Then we further investigated the expres-
sion of the Sirt3 in HCC specimens.
Methods
Patients and TMA construction
A total of 342 HCC patients were enrolled in this study at
the Liver Cancer Institute of Fudan University (Shanghai,
China) between 2007 and 2008, and informed consent was
obtained from each patient. The including criteria and
postoperative follow-up procedure were described previ-
ously [20,21]. The clinicopathological characteristics of
the patients were summarized in Table 1. The Barcelona
Clinic Liver Cancer (BCLC) staging system was applied to
classify the disease stage [22]. Tumor differentiation was
graded by the Edmond-son-Steiner grading system [23].
Time to recurrence (TTR) and overall survival (OS) time
were defined as the interval from primary surgical resec-
tion to the first recurrence or death, respectively. The
study was approved by the Zhongshan Hospital Research
Ethics Committee (Fudan University, China).
Tissue immunohistochemistry and evaluation system
Tissue microarray (TMA) was constructed as described
previously [24]. IHC was carried out according to appro-
priate protocols as described in our previous reports
[21]. Briefly, slides were deparaffinized in xylene and
hydrated through a graded alcohol series before being
placed in blocking solution to inhibit endogenous perox-
idase activity. The slides were incubated with primary
antibody (Sirt1 1:100, Epitomics; Sirt2 1:200, Epitomics;
Sirt3, 1:200 Abgent; Sirt4, 1:200 Abgent; Sirt5, 1:100
Abgent; Sirt6, 1:150 Abgent; Sirt7, 1:100 Abgent) at 4°C
overnight. Slides were then applied in the detectionsystem of Elivision™ Plus Kit and DAB, followed by
counterstaining with hematoxylin.
As a mitochondrial factor, we evaluated cytoplasmic ex-
pression of Sirt3 in HCC. A scoring system was applied as
previously described with some modifications [25-27]. In
brief, a staining index for each case was determined by
multiplying the score for intensity of cytoplasmic staining
(none = 0, weak = 1, strong = 2) with the score for propor-
tion of tumor cytoplasma stained (<5% = 0, 5%-25% = 1,
25%-50% = 2, 50%-75% = 3, >75% = 4) [21,26]. The results
were confirmed by two experienced pathologists who were
blinded to the clinicopathologic data of the patients.
Western blot analysis
The immunoblotting was carried out as previously de-
scribed [28]. In brief, about thirty micrograms of pro-
teins extracted from paired HCC and its adjacent tissues
were separated by SDS-PAGE, after which the protein
was transferred to polyvinylidene fluoride membranes
(Millipore), membrane-bound Sirt3 was detected with
rabbit anti-human Sirt3 (1:1000, Epitomics). GAPDH
(1:5000, KANGCHENG) was used as an internal control.
WB analysis was proceeded by the relative expression
of Sirt3 in peritumoral tissues compared with tumoral
tissues in each case of 51 specimen, by using GAPDH as
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tein level of superoxide dismutase 2 (SOD2) (1:1000,
Epitomics) and Sirt3 via WB analysis in another inde-
pendent 15 HCC specimen.
Statistics
Statistical analyses were carried out using Statistical
Package of the Social Sciences (SPSS version 17.0). χ2
test and paired t test were done as appropriate. Univari-
ate analyses were done using the Kaplan-Meier method
and compared by the long-rank test. Cox multivariate
analysis was used to adjust for potentially confounding
variables and to determine the independent prognostic
factors. The “minimum P value” approach [24,29] was
used to get optimal cut-off for the best separation be-
tween groups of patients related to TTR or OS. Unless
otherwise specified, all data were analyzed using two-tail
test and P < 0.05 was considered statistically significant.
Results
Patient profile
The detailed clinicopathological characteristics of the
patients are supplied in Table 1. The median follow-up was
42.9 months (range, 0.43-61.83 months; SD, 18.8 months).
At the last follow-up (March 31st, 2012), 158 patients
(46.2%) had recurrence. 125 patients (36.5%) died ofFigure 1 Representative immunohistochemical staining of Sirt3. The m
negative staining in Patient II (C) in tumor tissues, and strong staining of p
& 400×).recurrence (n = 103) or cirrhosis related complications
without recurrence (n = 22) (These data of follow up of pa-
tients were not shown in Table 1).
Immunohistochemical expression pattern of Sirt3 in
paired tumoral and peritumoral tissues
We found that the majorities of tumoral and peritumoral
tissues showed diffuse cytoplasmic expression pattern of
Sirt3 (Figure 1). Compared with paired peritumoral tis-
sues, tumoral tissues had significantly down-regulated
expression of Sirt3 (mean, 4.07 vs. 4.27, P = 0.003). Repre-
sentative cases of Sirt3 IHC staining were show in Figure 1.
The expression pattern of other sirtuin members was de-
scribed in the Supplementary Information (See Additional
file 1: Figure S1).
Prognostic significance of Sirt3 for HCC
By using the “minimum P value” approach, scoring value of
2 and 4 are the best cut-off value for intratumoral and peri-
tumoral Sirt3, respectively (See Additional file 2: Table S1).
On univariate analysis, patients with lower expression of
Sirt3 in tumor were prone to lower OS (Figure 2A,
P = 0.001) and shorter TTR (Figure 2B, P = 0.011). Other
clinicopathologic factors associated with OS or TTR were
shown in Table 2. Factors that showed significance by uni-
variate analysis were enrolled as covariate in a multivariateicrographs showed weak staining of Sirt3 in Patient I (A), nearly
eritumoral liver tissues (B, D) in patient I and II. (magnification100×
Figure 2 Kaplan-Meier analysis of OS and TTR for the expression levels of Sirt3. Kaplan-Meier analysis of OS and TTR for the expression
levels of intratumoral Sirt3 (A and B) and peritumoral Sirt3 (G and H). Subgroup analysis of Sirt3 expression in relation to OS and TTR indicated
that intratumoral Sirt3 had prognostic role when classified by BCLC stage A (C and D) and without thrombi (E and F).
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Table 2 Univariate and multivariate analyses of Sirt3 associated with recurrence and survival
TTR OS
Univariate Multivariate Univarate Multivariate
P value H.R. (95% CI) P value P value H.R. (95% CI) P value
BCLC stage A
γ-GT, U/L (≤54 vs >54) 0.003 1.646 (1.091–2.484) 0.016 0.003 1.718 (1.051–2.810) 0.028
AFP, ng/ml (≤20 vs >20) 0.013 1.574 (1.033–2.398) 0.032 0.060 NA NA
Tumor size, cm (≤5 vs >5) <0.001 2.292 (1.515–3.470) <0.001 <0.001 3.150 (1.952–5.084) <0.001
Tumor number (single vs multiple) 0.948 NA NA 0.726 NA NA
Tumor capsule (yes vs no) 0.296 NA NA 0.690 NA NA
Differentiation (well vs poor) 0.429 NA NA 0.550 NA NA
Mean density score (low vs high)
iSirt3(2) 0.008 0.591 (0.396–0.884) 0.011 <0.001 0.404 (0.251–0.650) <0.001
pSirt3(4) 0.020 0.538 (0.316–0.914) 0.022 0.278 NA NA
TMA assays
Age, year (≤52 vs >52) 0.173 NA NA 0.787 NA NA
Gender (female vs male) 0.616 NA NA 0.654 NA NA
HBV infection (no vs yes) 0.903 NA NA 0.168 NA NA
Liver cirrhosis (no vs yes) 0.803 NA NA 0.225 NA NA
ALT, U/L (≤75 vs >75) 0.177 NA NA 0.225 NA NA
γ-GT, U/L (≤54 vs >54) <0.001 1.563 (1.121–2.177) 0.008 <0.001 1.471 (1.003–2.159) 0.046
AFP, ng/ml (≤20 vs >20) 0.004 1.474 (1.048–2.072) 0.023 0.014 1.379 (0.936–2.031) 0.098
Tumor size, cm (≤5 vs >5) <0.001 1.830 (1.314–2.549) <0.001 0.000 2.919 (2.019–4.220) <0.001
Tumor number (single vs multiple) 0.057 NA NA 0.069 NA NA
Tumor capsule (yes vs no) 0.096 NA NA 0.167 NA NA
Differentiation (well vs poor) 0.162 NA NA 0.124 NA NA
Tumor thrombi (no vs yes) 0.001 1.506 (1.072–2.116) 0.021 <0.001 1.658 (1.146–2.399) 0.009
TNM stage (I vs II/III) <0.001 NA NA <0.001 NA NA
BCLC stage (A vs B/C) 0.001 NA NA <0.001 NA NA
Mean density score (low vs high)
iSirt3(2) 0.011 0.705 (0.514–0.967) 0.031 0.001 0.558 (0.392–0.795) 0.001
pSirt3(4) 0.017 0.674 (0.450–1.009) 0.047 0.023 0.611 (0.381–0.979) 0.031
Note: Univariate analysis was calculated by the Kaplan–Meier method (the log-rank test). Multivariate analysis was done using the Cox multivariate proportional
hazards regression model in a stepwise manner (backward, likelihood ratio). AFP, a-fetoprotein; 95% CI, 95% confidence interval; γ-GT, γ-glutamyl transferase;
HR, hazard ratio; NA, not applicable; OS, overall survival; TTR, time to recurrence;TNM, tumor-node-metastasis; BCLC, Barcelona Clinic Liver Cancer.
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vealed that intratumoral Sirt3 was an independent prog-
nostic indicator for OS (Table 2, P = 0.001), and retained
the prognostic power for predicting recurrence (Table 2,
P = 0.031). Furthermore, we found that intratumoral Sirt3
showed prognostic role in BCLC stage A patients (Figure 2C
and D, OS, P < 0.001; TTR, P = 0.008), and in no vascu-
lar invasion subgroups (Figure 2E and F, OS, P = 0.002;
TTR, P = 0.008). Intratumoral Sirt3 also showed prognos-
tic role in other groups when classified by the following
variables (Table 3): large tumor (>5 cm) (OS, P = 0.003;
TTR, P = 0.046), single tumor (OS, P < 0.001; TTR, P =
0.011), tumor with encapsulation (OS, P = 0.002; TTR,P = 0.036), tumor differentiation grade I-II (OS, P <
0.001; TTR, P = 0.007).
Meanwhile, patients with higher expression of Sirt3 in
peritumoral tissues were prone to higher OS (Figure 2G,
P = 0.023) and longer TTR (Figure 2H, P = 0.017), and
multivariate analysis also revealed peritumoral Sirt3
had independent prognostic value for both OS (Table 2,
P = 0.031) and TTR (Table 2, P = 0.047). Peritumoral
Sirt3 also showed prognostic role in groups when classi-
fied by the following variables (Table 3): single tumor
(OS, P = 0.023; TTR, P = 0.016), tumor differentiation
grade I-II (OS, P = 0.028; TTR, P = 0.009). The afore-
mentioned results suggested that down-regulation of
Table 3 Survival analysis of Sirt3 expression in HCC
patients when stratified by clinicopathologic factors
Variables
iSirt3-TTR iSirt3-OS pSirt3-TTR pSirt3-OS
P value P value P value P value
TNM
I 154 0.110 0.059 0.078 0.100
II/III 188 0.066 0.004 0.020 0.031
BCLC
A 233 0.008 < 0.001 0.020 0.278
B/C 109 0.690 0.366 0.204 0.020
HBV infection
No 94 0.037 0.127 0.343 0.217
Yes 248 0.095 0.003 0.033 0.051
Cirrhosis
No 303 0.029 0.003 0.046 0.059
Yes 38 0.151 0.076 0.131 0.148
AFP
≤20 132 0.075 0.078 0.371 0.334
>20 210 0.104 0.006 0.049 0.079
γ-GT (U/L)
≤54 163 0.639 0.208 0.025 0.111
>54 179 0.012 0.002 0.384 0.164
Tumor size
≤5 229 0.127 0.045 0.094 0.093
>5 113 0.046 0.003 0.062 0.108
Tumor number
1 297 0.011 < 0.001 0.016 0.023
≥2 44 0.547 0.903 0.566 0.585
Tumor thrombi
No 249 0.008 0.002 0.015 0.263
Yes 93 0.706 0.154 0.386 0.024
Tumor capsule
Yes 183 0.036 0.002 0.200 0.191
No 159 0.209 0.124 0.035 0.064
Differentiation
Well 255 0.007 < 0.001 0.009 0.028
Poor 87 0.856 0.879 0.838 0.535
Note: χ2 tests for all the analysis. AFP, alpha-fetoprotein, γ-GT, γ-glutamyl
transferase. OS, overall survival; TTR, time to recurrence.
Table 4 Correlation of clinicopathologic characteristics
with Sirt3 expression
iSirt3 pSirt3
Characteristics Low High P value Low High P value
Gender Male 124 166 0.649 219 71 0.632
Female 24 28 41 11
Age (Years) ≤52 75 93 0.616 135 32 0.051
>52 73 101 125 49
HBV infection No 47 47 0.122 68 26 0.296
Yes 101 147 192 55
Liver cirrhosis No 132 172 0.877 231 72 0.991
Yes 16 22 29 9
ALT (U/L) ≤75 127 176 0.157 229 73 0.613
>75 21 18 31 8
AFP (ng/ml) ≤20 51 81 0.170 90 42 0.005
>20 97 113 170 39
γ-GT (U/L) ≤54 63 100 0.100 120 43 0.275
>54 85 94 140 38
Tumor size (cm) ≤5 95 134 0.342 174 55 0.870
>5 53 60 86 26
Tumor number 1 132 166 0.322 229 68 0.333
≥2 16 28 31 13
Tumor thrombi No 103 146 0.244 188 61 0.595
Yes 45 48 72 20
Encapsulation Yes 72 111 0.115 190 64 0.368
No 76 83 70 17
Differentiation Well 109 146 0.735 136 47 0.285
Poor 39 48 124 34
TNM stage I 64 90 0.562 122 32 0.242
II/III 84 104 138 49
BCLC stage A 96 137 0.258 178 55 0.925
B/C 52 57 82 26
Note: χ2 tests for all the analysis. AFP, alpha-fetoprotein; γ-GT, γ-glutamyl
transferase ; OS, overall survival ; TTR, time to recurrence.
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ated with unfavorable prognostic performance of HCC.
The prognostic value of other Sirtuin members were
shown in the Supplementary Information (See Additional
file 3: Table S2).
Correlation between Sirt3 and clinicopathological features
Both tumoral and peritumoral Sirt3 expression level
were not correlated with tumor size, tumor numbers,differentiation, encapsulation or vascular invasion. We
found that Sirt3 expression level in peritumoral tissues
was associated with AFP (Table 4). Peritumoral tissues
with higher AFP were prone to have lower expression of
Sirt3.
Sirt3 expression in HCC and peritumoral tissues
By WB detection of Sirt3 in 51 paired tumoral and peritu-
moral tissues, Sirt3 was significantly down-regulated in tu-
moral tissues compared to peritumoral tissues (Figure 3,
P = 0.0042). As shown in Additional file 4, 9 of 51 speci-
men had higher expression of Sirt3 in tumor compared
with paired peritumoral tissues, by using GAPDH as an
internal control. In the 9 cases as mentioned above, 3 had
Figure 3 Western blot analysis of Sirt3 in HCC and peritumoral
liver tissues. (A) WB detection of Sirt3 protein in 51 paired tumors
(T) and peritumoral tissues (pT). GAPDH served as a loading control.
(B) Sirt3 protein level obtained by densitometric scaning was
significantly down-regulated in tumors compared to peritumoral
tissues (P = 0.0042).
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expression of Sirt3 in peritumoral tissues had recurrence
(P = 0.776). Meanwhile, no difference was shown regard-
ing the disease stage in 9 cases compared with residual 42
cases (See Additional file 5). This result was in accordance
with the IHC analysis as mentioned and was supported by
previous studies [19,30].
Correlation between the expression of Sirt3 and SOD2 in
HCC and peritumoral tissues
By WB detection of Sirt3 and SOD2 in independent 15
paired tumoral and peritumoral tissues, we showed that
the expression of SOD2 was positively correlated with
Sirt3 (r = 0.5418, P = 0.037) (See Additional file 6).
Discussion
We systematically investigated the expression pattern and
prognostic importance of the Sirtuins family for HCC
undergoing radical resection for the first time. After a
comprehensive analysis by IHC studies, we found that
Sirt3 had more prognostic value.
In this study, we reported the down-regulation of Sirt3
in tumoral specimens compared with peritumoral tissues
at the protein level, both by IHC staining and WB ana-
lysis (Figure 1 and Figure 3). The discrepancy of Sirt3
expression between tumoral and peritumoral tissues was
consistent with the results of other cancer studies [6,19].
To our knowledge, ROS act as the second messengers to
stimulate cell proliferation, apoptosis, and gene expres-
sion at the submicroscopic level, and excessively elevated
levels of ROS can produce oxidative stress which leads to
a variety of diseases, including cancer, aging, and neuro-
logic disorders [31]. It has been proposed that Sirt3 regu-
lated mitochondrial acetylation and ROS generation, and
therefore mediated the tumor-inhibiting role in cancer. In
consistent with this hypothesis, we found that the de-
creased expression level of intratumoral Sirt3 could inde-
pendently predict elevated risks of tumor recurrence and
patients’ death.
Of note, Sirt3 reduces cellular ROS levels via SOD2, a
major mitochondrial antioxidant enzyme [32,33]. Sirt3
deacetylates two critical lysine residues on SOD2 and
promotes its antioxidative activity [34]. Importantly, the
abilities of SOD2 to reduce cellular ROS and promote
oxidative stress resistance is greatly enhanced by Sirt3.
In consistent with this relationship between SOD2 and
Sirt3, our results showed that the expression of SOD2
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mens, which supported that Sirt3 may reduce the ex-
pression level of ROS via the activation of SOD2.
In recent years, high recurrence rate remains a major
barrier to improve postoperative outcome of HCC. So
the early prediction of recurrence in HCC patients after
resection is obviously important for timely treatment,
which may lead to better clinically outcome, especially
in patients with early stage HCC [35]. Compared to the
advanced-stage HCC, the prognosis of early-stage HCC
is far from homogenous, and lacks ideal indicators
[36,37]. Now our results showed that in BCLC stage A
or no vascular invasion group of patients, intratumoral
Sirt3 expression showed the ability to predict the risk of
recurrence and patient survival (Figure 2). Its independ-
ent prognostic value in early BCLC stage HCC patients
is of clinical importance, which maybe a useful bio-
marker to identify patients who should be monitored
frequently and then be subjected to adjuvant therapy like
antioxidant therapy [38].
In our study, the patients with lower intratumoral
Sirt3 expression showed not only higher recurrence but
shorter survival times after curative resection, which was
partly consistent with the results of a previous study
[30]. The different results of recurrence in multivariate
analysis between us may partly due to the different scor-
ing systems of IHC evaluation and the methods of the
definition of cutting off score. However, both results
suggested intratumoral Sirt3 as an independent prognos-
tic biomarker for OS in HCC patients after resection.
Recently, many studies revealed that robust production
of ROS played important roles in hepatocarcinogenesis,
which could directly induce DNA damage and alter gene
expression [39,40]. Furthermore, there existed a high in-
cidence of intrahepatic metastasis and recurrence after
resection [41-43], which suggested that peritumoral en-
vironment was important. In our results, low expression
of peritumoral Sirt3 was also associated with HCC re-
currence and poor survival after hepatectomy. Therefore,
peritumoral Sirt3 may serve as a protector of recurrence
of HCC through preventing the generation of ROS.
These results highlight the important role of remanent
liver in recurrence and metastasis, and will be helpful in
shaping postoperative strategy for the prevention of re-
currence after hepatectomy.
Conclusions
This present study indicated that both intratumoral and
peritumoral Sirt3 expression were associated with prog-
nosis in HCC. Moreover, we demonstrated that the
down-regulation of Sirt3 in HCC indicated aggressive
tumor behaviors and predicted an unfavorable clinical
outcome. Also, Sirt3 may be a useful biomarker to iden-
tify the BCLC stage A group of patients at high risk ofpost-operative recurrence. Therefore, further study elu-
cidating the molecular pathogenesis of the multi-facet
Sirt3 in HCC may lead to more effective and specific
therapies against this intractable cancer.
Additional files
Additional file 1: Figure S1. Representative IHC staining of Sirt1, 2, 4, 5,
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Additional file 6: Correlation between expression level of Sirt3 and
SOD2 in HCC patients. 15 cases were studied.
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